Mediclinic International plc
(Incorporated in England and Wales)
Company Number 8338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic" or "the Company")
20 March 2017
BOARD COMMITTEE CHANGES
The Company announces that, following a review of the composition of the Board Committees, the membership of the Committees will be as follows, with effect from 17 March 2017.
· The Audit and Risk Committee will continue to be chaired by Desmond Smith and its other members will comprise Alan Grieve, Seamus Keating and Trevor Petersen.
· The Remuneration Committee will continue to be chaired by Trevor Petersen and its other members will comprise Prof Dr Robert Leu and Seamus Keating.
· The Nomination Committee will be chaired by Dr Edwin Hertzog and its other members will comprise Jannie Durand (with Pieter Uys as his alternate), Prof Dr Robert Leu, Trevor Petersen and Desmond Smith.
· The Clinical Performance and Sustainability Committee will continue to be chaired by Dr Edwin Hertzog and its members will comprise Nandi Mandela, Danie Meintjes and Prof Dr Robert Leu.
· The Investment Committee will continue to be chaired by Dr Edwin Hertzog and its other members will comprise Jannie Durand (with Pieter Uys as his alternate), Alan Grieve, Seamus Keating, Danie Meintjes and Jurgens Myburgh.
Mediclinic's primary listing is on the Main Market of the LSE, with secondary listings on the JSE in South Africa and on the NSX in Namibia.
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
For further information please contact:
Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600